FDA Approves Atezolizumab in Combination with Chemotherapy for Stage III Mismatch Repair Deficient Colon Cancer

The U.S. Food and Drug Administration (FDA) has approved atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients aged two years and older with Stage III mismatch repair deficient (dMMR) colon cancer. This regulatory action provides a new treatment option for this specific patient population.